Life Sciences Archive » April, 2024

Life Sciences - April, 2024

300 articles

• Ex-Olympus Exec Says He Was Fired For Flagging FDA Issue
• Judge Strikes Parts Of NC Law Restricting Abortion Drug
• Tech. Orgs Deny Being 'Apple's Puppets' In Watch Ban Fight
• Chase Can't Escape Medical Services Co.'s Defamation Suit
• Pharmacyclics Can't Score Fees After Imbruvica Patent Win
• Amgen Cuts Deal To End Bone Drug IP Suit Against Sandoz
• SEC Fines 3 Men For Insider Trading On Zogenix Buyout
• BCBS Says Federal Drug Law Preempts NM Medical Weed Row
• Pfizer Can't Slip COVID-19 Vax Suit, Texas Tells Court
• Drug Company Can't Escape Texas Counties' Opioid MDL
• 3rd Circ. Preview: Kavanaugh Classmate Takes On HuffPost
• Judge Tosses LTL's Suit Over Article Linking Talc To Cancer
• FTC Continues To Target 'Junk' Drug Patents
• Vaxart Investors Want Sanctions Over Deleted Texts
• Feds Endorse Easing Marijuana Status In Big Policy Shift
• Don't Miss It: McDermott, Paul Weiss Lead Month's Hot Deals
• Think Like A Lawyer: Follow The Iron Rule Of Trial Logic
• Medical Device Biz Hologic To Buy UK Rival For $310M
• Pfizer Inks $25M Deal Ending Leftover Effexor Antitrust Claims
• Judge Rejects 2 Challenges To Medicare Drug Price Talks
• Sandoz Says Biopharma Biz Added 'Poison' To Market
• Mistrial Called In $86M Stent Patent Case Against Medtronic
• Boehringer Accused Of Monopolizing Inhaler Product Market
• Pharma Co. Hit With Investor Suit Over Liver Drug Trials
• HHS Delays Menthol Cigarette Ban Indefinitely
• Amid Backlash, FDA Extends Control For Lab-Developed Tests
• Catching Up With Delaware's Chancery Court
• AI Pharma Co. Sued By Investor Over Handling Of Fired CEO
• Alcon Owes $34M In Glaucoma Patent Row, Jury Finds
• 4th Circ. OKs Sanctions Against Law Firm In Bestwall Ch. 11
• PTAB Rejects Masimo's Concurrent Bid To Review Apple Patent
• Judge Rejects Class Certification Of Seizure Drug Customers
• The Art Of Asking: Leveraging Your Contacts For Referrals
• Connecticut Firm Seeks $500K Fee In Magnesium Class Action
• Deciphera Stock Soars On $2.4B Deal With Japan's Ono
• Justices To Weigh RICO Injury Scope In CBD Case
• Philips Inks $1.1B Deal To Resolve CPAP Injury Claims
• Law360 Reveals Titans Of The Plaintiffs Bar
• Ex-McKinsey Partner Says Firm Made Him Opioids 'Scapegoat'
• New FDA Official Talks Food Safety After Formula Outbreak
• Ex-USPTO Solicitor Heads To Carmichael IP
• Trending At The PTAB: Permissible New Reply Arguments
• Latham, Akin Beat NJ Suit Over Alleged IP Theft Scheme
• Ga. Residents Want In On $300M Monkey Farm Fight
• Wave Of Final Rules Reflects Race Against CRA Deadline
• 'Beauty From Within' Trend Poses Regulatory Risks For Cos.
• QuidelOrtho Execs Lied About COVID Test Revenue, Suit Says
• Astellas Can't Block Generic Myrbetriq Amid Patent Suit
• CureVac, Acuitas Reach Deal In COVID Vax Patent Dispute
• GSK Hits Pfizer And BioNTech With COVID Vaccine Patent Suit
• Stryker Says Sanctions Bid Goes 'Galaxies Beyond' Law
• 3rd Circ. Lets Mallinckrodt Off Sanofi's Royalty Hook
• Becton BIPA Suit Gets Cut Short Under Health Exception
• Philips Gets $506M Economic Loss Deal OK'd In CPAP MDL
• McKesson May Change How AKS-Based FCA Claims Are Pled
• NC Hospital Leader Condemns FTC's Merger Block Bid
• Ex-Burns & Levinson Life Sciences Chair Joins Polsinelli
• Conn. Judge In Drug Price-Fixing Suit Reveals Day Pitney Ties
• Class Counsel Seeks $31M From $93M Lipitor Settlement
• Being An Equestrian Makes Me A Better Lawyer
• Wachtell Steers Perrigo In €275M Unit Sale To Pharma Biz
• Motley Rice, Morgan & Morgan Among Ozempic MDL Leaders
• DEA's Upcoming Decision On Cannabis Likely To Be Litigated
• UPMC Affiliate Can't Avoid False Claims Suit Over NIH Grant
• NGM Biopharma Investor Seeks Stock Appraisal In Del.
• FDA Can Keep Most Docs Hidden From Juul's FOIA Request
• Joe Rogan Brain Health Supplements Don't Work, Suit Claims
• 7th Circ. Mootness Fee Case May Curb Frivolous Merger Suits
• Fintiv Denials Are On The Rise At PTAB
• Private Equity Lag Continues To Stunt M&A Growth
• 4 Ways To Refresh Your Law Firm's Marketing Strategy
• Calif. Fertility Clinic Implanted Dead Embryos, Couples Say
• Medtronic Patent Fight With Axonics Set For September Trial
• GoodRx Hid Revenue Reliance On Kroger, Suit Claims
• Israeli Biotech Files Ch. 15 To Implement Take-Private Deal
• Ex-Takeda Worker, Boyfriend To Plead Guilty In Invoice Scam
• Drugmakers Hit With RICO Suit Over Insulin Price Hikes
• Fenwick, Covington Build $750M Sale Of Pharmaceutical Biz
• Pre-Merger Deal Prompts Pharma Co. Derivative Suit In Del.
• Cos. Must Prepare For Calif. Legislation That Would Ban PFAS
• Colo. Neural Privacy Law Has Attys Scratching Their Heads
• HHS Finalizes Rule Bolstering Abortion Privacy Protections
• Eli Lilly Tells Fed. Circ. $177M Patent Loss Was Rightly Axed
• 9th Circ. Backs Class Cert. In Pet Supplement False Ad Suit
• J&J Fired Worker For Old Case Against New Boss, Suit Claims
• J&J Hit With $45M Talc Verdict In Illinois Cancer Trial
• Opioid Marketer Completes $1.5M Damages Settlement With Del.
• FDA Warning Letter Tightens Reins On 'Research Only' Labels
• Broker In Penny Stock Scheme Says SEC Is Forum Shopping
• DEA Tells 9th Circ. 'Right To Try' Doesn't Rewrite CSA
• J&J Says Worker's Drug Costs Suit Misses Big Picture
• Catching Up With Delaware's Chancery Court
• Thermo Fisher Says Rival Is Raiding Its Workforce
• Supreme Court Won't Review Vanda's IP Obviousness Appeal
• Allergan To Face Kickback Claim In Suit Over Child Botox Use
• Judge Mulls Axing Biomedical Cos.' $25M Punitive Damages
• Flint Class Urges Approval Of $25M Water Firm Settlement
• Walgreens Inks $110M Deal To End Philly Opioid Crisis Suit
• J&J Unit Sued Over Defective Knee Replacements
• Blumenauer: This 4/20 Will Be The Last For Schedule I Pot
• Practical Pointers After Fed. Circ. Double-Patenting Decision
• Highlights From The 2024 ABA Antitrust Spring Meeting
• UK Litigation Roundup: Here's What You Missed In London
• USPTO Reveals Scaled-Back Plan For New Patent Board Rules
• NY Fertility Clinic Must Face Lost, Damaged Embryos Suit
• EU Antitrust Chief Says Merger Tool Not A 'Power Grab'
• Pharma Ex-Exec Can't Revive $12M Underpayment Suit in US
• J&J Notches Win In Fla. Talcum Powder Trial
• Pharma Co. Wants Tribe's Opioid Suit To Stay In Federal Court
• Endo Pleads Guilty To Marketing Opioids As 'Crush Proof'
• 23andMe Taps Dechert To Review CEO Buyout Proposal
• FDA Head Gets GOP Rep.'s Rebuke Over Pot Rescheduling
• Biotech Co. NanoString Lands $393M Bid At Ch. 11 Auction
• Strategies For Challenging A Fla. Grand Jury Report's Release
• Trial-Ready Paraquat MDL Cases Tossed After Testimony Axed
• Walgreens Investors' $36M Deal In Opioid Suit Gets First OK
• PTC Therapeutics Settles Shareholder Suit Over Director Pay
• United Therapeutics Can't Bar Rival Lung Disease Drug
• Kraft Sued Over Lead Contamination In Lunchables
• J&J Tells Jurors To Look To Evidence And Science In Talc Trial
• Karuna Investor Ends Suit After Bristol-Myers Seals $14B Deal
• Jury To Decide Fault Of Driver In Spray-Huffing DUI Death
• 3 Takeaways From Revived Obviousness Case On J&J Patent
• FDA's Foot-Dragging On Menthol Ban Sparks Frustration
• FDA Denies Marketing For 65 MNGO Disposable E-Cigarettes
• FDA Tells Justices It Has A Better Vape Case In Mind
• SEC Has Careful Eye On Disclosures Amid Israel-Hamas War
• 'Ringleader' Of Black Market HIV Drug Scam Gets 9 Years
• Patent Lessons From 8 Federal Circuit Reversals In March
• Manatt Adds NY Bankruptcy, Financial Regulatory Partners
• WashU Medical School Settles Claims Of Asylee Bias, Firing
• Ex-Pharma Exec's Contempt Plea Rejected By Judge
• Elliott Waives BioMarin Board Deal, Moots Del. Suit
• A Look At Ex Parte Seizures 8 Years Post-DTSA
• Whitewater Kayaking Makes Me A Better Lawyer
• House Panel Takes Aim At Change Healthcare, FTC Over Hack
• Eli Lilly's Insulin Price Cap Deal Collapses After Cert. Denial
• NC Treasurer Backs FTC On Hospital Merger Challenge
• IBM Gained Most AI Patents By Far In 2023
• AI In The Operating Room: Liability Issues For Device Makers
• Del. Lessons For Director-Nominees On Sharing With Activists
• Life Sciences Group Of The Year: Fenwick
• 10 Years After Alice, Predictability Debate Lingers
• This Earth Day, Consider How Your Firm Can Go Greener
• Taro Inks $36M Investor Deal Over Generics Price-Fixing
• Chancery Denies Forte Biosciences' Bid To Toss Investor Suit
• Years After Args, 7th Circ. Continues Mootness Fee Attack
• TTAB Sides With Pharma Co.'s Opposition To 'SageForth' TM
• Hold This COVID Vax Patent Case, Judge Recommends
• Catching Up With Delaware's Chancery Court
• Orrick Adds Kramer Levin Life Sciences Head In NY
• Pharmacy, Courier Co. Settle Driver's Classification Suit
• Justices Won't Nix FDA Labeling Preemption For State Claims
• Life Sciences Group Of The Year: Cooley
• Moderna, Pfizer COVID Vax IP Suit Paused Amid PTAB Review
• Ex-Biotech CEO Gets 7 Years In Fake COVID Test Case
• DEA Unlawfully Pushing Psychedelics Ban, Researcher Says
• Abbott Labs Gets Price Claims Tossed In Baby Formula MDL
• Questions Persist After Ruling Skirts $925M TCPA Award Issue
• Benzene Contamination Concerns: Drugmakers' Next Steps
• Ex-Pfizer Worker's Pal Avoids Prison In Insider Trading Case
• Trade Groups Urge Senators To Advance Patent Reform Bills
• States Should Follow Federal Lead On Expert Evidence Rules
• Woman Pleads Guilty To $1.3M COVID Tax Credit Fraud
• Life Sciences Group Of The Year: Latham
• US-Based MSD Broke Ban On Using 'Merck' In UK, Court Finds
• Zoll Says 'Cookie-Cutter' Hack Claims Don't Show Harm
• EU Approves Biotech Co. Illumina's Plan To Divest Grail
• Asbury Park Escapes Pot Co.'s Zoning Board Conspiracy Suit
• Sandoz Says Feds Misclassified Generics As 'Innovator Drugs'
• Fed. Circ. Blocks Alvogen Generic Of Bausch Diarrhea Drug
• FDA Commissioner Says Congress Must Act On Hemp, CBD
• 9th Circ. Nixes 'Super Snap Removals' In Dexcom Suits
• Birth Control Injury Claims Barred From Conn., Court Told
• Deals Rumor Mill: US Steel, Germany's Stada, Paramount
• Del. Justices OK Denial Of Icahn-Illumina Midcase Appeal Bid
• Medtronic Can't Ditch Ex-Sales Rep's Retaliation Claim
• The Pros And Cons Of NIST's Proposed March-In Framework
• Kirkland, Jones Day Build $787.5M Sale Of Steris' Dental Unit
• Life Sciences Group Of The Year: Sullivan & Cromwell
• Pfizer Unit Cuts $39M Deal Ending Effexor Antitrust Claims
• DOJ Hits Regeneron With False Claims Act Suit Over Eylea
• Del. Justices Probe Validity Of Advance Notice Bylaws
• 9th Circ. Mostly Affirms Industry Ban For COVID PPE Delays
• Dems Introduce Bill To Codify Policy Barring Judge Shopping
• 4th Circ. Sides With CMS' Definition Of 'Line-Extension Drug'
• Skadden, Fenwick Lead $4.9B Alpine Immune Sciences Sale
• Pharmacy Gets Eli Lilly's Mounjaro Suit Tossed
• Justices Asked To Ban FCA Suits Relying On Patent Reviews
• Moderna Says Pfizer Is PTAB 'Tea-Leaf-Reading' In Vax IP Row
• Federal MDL Rule Benefits From Public Comments
• 1st Circ. Says Appellant's Death Erases Conviction
• Practicing Law With Parkinson's Disease
• Life Sciences Group Of The Year: Morrison Foerster
• Ginkgo Bioworks SPAC Investors Sue In Del. After Stock Drop
• After Uproar, New MDL Rule Advances With Attys Assuaged
• Investor Can't Get Approval Of Hong Kong Award In Calif.
• Philips, Feds Enter Consent Decree Over Sleep Apnea Devices
• Pfizer Cancer Drug Way Too Expensive, Biden Told
• HK Arbitrator Halts Commercialization Of Leukemia Treatment
• Former Pharma Exec Can't Oust Judge In Contempt Case
• Endo Sues FDA Over Generic Adrenalin Approvals
• Biotech Co. Insiders Sued In Del. Over $200M PIPE Deal Gain
• Tech M&A Reigns Supreme In Q1 After Rare Hiccup In Q4
• When Trade Secret Protection And Nat'l Security Converge
• The Merger Cases That Will Matter At ABA Antitrust Meeting
• Life Sciences GCs On Tighter Regs, Outside Counsel Advice
• Calif. Verdict Showcases SEC's New 'Shadow Trading' Theory
• Jenner & Block Recruits Ex-Sheppard Mullin IP Litigator In SF
• Court OKs Decision Clearing Contractor Of Missed IP Deadline
• Playing Hockey Makes Me A Better Lawyer
• Target's Acne Treatments Contain Benzene, Customer Says
• Walmart Beats Investor Suit Over Opioid Probe Disclosures
• SEC 'Shadow Trading' Victory Could Bring DOJ Knocking
• Roche Again Beats Ex-Service Members' Antimalarial Drug Suit
• 9th Circ. Urged To Revive J&J, Bausch Talc False Ad Suit
• La. Drug Caps Conflict With Federal Law, AbbVie Says
• PE Firm Calls FTC's Antitrust Claims 'Many Yesterdays' Old
• Catching Up With Delaware's Chancery Court
• FDA Finds No Asbestos In Cosmetic Talc Products
• For Lawyers, Pessimism Should Be A Job Skill, Not A Life Skill
• Goodwin Adds 5-Atty Tech Team From Cooley In Boston
• Kirkland-Led Vista Buying Medtech Co. 'Model N' For $1.25B
• Apple Asks Fed. Circ. To Upend ITC Watch Feature Ban
• 'Take The Win,' Judge Tells Texas In HHS Abortion Pill Suit
• Abbott Settles TM Suit Over Gray Market Diabetes Test Strips
• Judge Lourie's Dissent Revives Debate Over FDA Safe Harbor
• Fed. Circ. Says Sumitomo's Expired Drug Patent Moots Appeal
• Texas Man Gets 7 Years For COVID Testing Fraud
• Ex-Biopharma Officer Seeks Defense Fees Over Fraud Suit
• Mich. Plaintiffs Bar Prepares For Growth After Policy Shifts
• Publix Wants Ga. High Court Input On Opioid Public Nuisance
• Jury Finds Pharma Exec 'Shadow Traded' With Inside Info
• HHS Opioid Rule Generally Benefits Providers And Patients
• New Chancery Challenge Launched To Board-Investor Pacts
• Mo. High Court Affirms Co.'s Medical Pot License Denial
• Gunderson, Sidley Steer Biotech's Scaled-Down $110M IPO
• Trump's NY Civil Fraud Trial Spotlights Long-Criticized Law
• UK Litigation Roundup: Here's What You Missed In London
• Freshfields Reps J&J On $13.1B Deal For Shockwave Medical
• SEC Points Jury To 'Coincidence' In Shadow Trading Trial
• Tribes And McKinsey Take Final Step In $39.5M Opioid Deal
• NY AG Asked To Weigh In On Multiple Sclerosis Drug Fight
• Latham Led Firms In 1st Quarter IPOs As Outlook Brightens
• Microsoft Unit Gets Fed. Circ. Alice Win On Imaging Patents
• Novo Holdings, Catalent Reset Review Clock On $16.5B Deal
• Structure Defense Remains In FTC Hospital Case, But Not Hearing
• Nurses Want To Merge DaVita Wage Suits Over Unpaid Breaks
• Higher Ed Groups Warn Of 'Radical Shift' In Suicide Liability
• UK Billionaire Lewis Avoids Prison For Insider Trading
• Squire Patton Adds Polsinelli Enviro Atty Pair In Denver
• Requiring Leave To File Amicus Briefs Is A Bad Idea
• Boston Scientific's $3.7B Axonics Buy Under FTC Microscope
• 2 Recent Suits Show Resiliency Of Medicare Drug Price Law
• Kirkland-Led SK Capital Raises $2.95B For 6th PE Fund
• Sanofi Plans To Settle 4,000 Zantac Cancer Claims
• Accused 'Shadow Trader' Takes Stand To Slam SEC's Case
• Microsoft Notches Fed. Circ. Win In 3D Imaging Patent Fight
• UK Billionaire Lewis Agrees To $1.64M Insider Trading Penalty
• Philly Injection Site Org. Isn't Religious, Judge Rules
• Sen. Durbin Urged To Pass Legislation To Curb Judge Shopping
• 4 Ways To Motivate Junior Attorneys To Bring Their Best
• Genmab Builds Oncology Portfolio With $1.8B Deal
• McDermott Adds Ex-Baker McKenzie Tax Pro In Chicago
• Hospital Workers' Vax Free Speech Suit Falls Flat At 6th Circ.
• Pharma Exec, Cousin Cop To Insider Trading On Kodak Loan
• Defense Attys Must Prep For Imminent AI Crime Enforcement
• Alaska Judge Tosses Opioid Nuisance Case Against Pharmacies
• 9th Circ. To Hear Ex-Theranos Execs' Criminal Appeals In June
• Lupin Scores Win In Rosacea Patent Fight With Galderma
• Theseus Investor Seeks Appraisal After Concentra Merger
• Teva Has Remedy For Generic EpiPen Takings, Colo. Says
• Fed. Circ. Seems Ready To Revive Amarin's Skinny Label Suit
• Mich. Warns PFAS Ruling Could Fuel More Agency Challenges
• NM Medical Cannabis Insurance Row To Stay In Federal Court
• Daiichi Gets Award Nixing Seagen Cancer Drug Claims OK'd
• Planning For Healthcare-Private Equity Antitrust Enforcement
• Why USPTO Should Issue Inherency Guidance Memo
• McCarter & English's Client Contract Win Heads To Mediation
• How Purdue Pharma High Court Case May Change Bankruptcy
• Feds Seek Leniency For UK Billionaire Lewis In Trading Case
• 3 Health Insurance Paths For Psychedelic-Assisted Therapy
• Serving As A Sheriff's Deputy Made Me A Better Lawyer
• Acorda Therapeutics Hits Ch. 11, Plans $185M Drug Sale
• Inotiv Can't Toss Investor Suit Over Feds' 'Puppy Mill' Probe
• Pharma Co. Beats Investor Suit Over Wrinkle Drug Approval
• Apple, Intel Again Lose Fintiv APA Challenge In Calif. Court
• Optical Co. Beats Investor Suit Over Pandemic Staffing Levels
• 'Unreliable' Theory Dooms City's Acthar Antitrust Cert. Bid
• Fed. Circ. Revives Challenges To J&J Schizophrenia Drug
• Catching Up With Delaware's Chancery Court
• Fears About The End Of Chevron Deference Are Overblown
• Ex-Pharma Co. Exec Denies Signing Noncompete Deal
• J&J Opted To 'Deny' Talc-Cancer Link, Jury Told
• Gunderson-Led Contineum Joins Pipeline Eyeing $150M IPO
• Fla. High Court Says Voters Will Choose Whether To Legalize Pot
• Negotiating Milestones In Pharma Licenses Requires Care
• Masimo Rips Politan's New Attempt To Grab Board Seats
• Eiger BioPharmaceuticals Hits Ch. 11 With $53.1M Debt
• Former Minn. Chief Justice Instructs On Writing Better Briefs